Havecon builds this specially developped and designed greenhouse for Stenocare.
The Danish company has signed a significant contract to establish a 0.1 hectare, state-of-the-art cultivation facility.
For more than a year, Stenocare has been pursuing innovative ways to combine the benefits of scale from green-house cultivation of medical cannabis with the advantages of highly controlled production. In pursuit of this, Stenocare has selected us as Havecon Horrticultutal Projects to co-develop a unique technology/facility that meets extreme demands for control of light, climate and 100% pesticide free in-door cultivation, at scale. This includes 24/7 environmental control through application of “pharma-standard” technology involving air filtration, active climate control with positive pressurized rooms, water treatment and continuous monitoring of all relevant quality parameters and processes.
The project is now ready to commence. Therefore, Stenocare has today entered into a turnkey construction contract with us to build the first such facility in the world. The commercial terms and technical specifications remain undisclosed for competitive reasons, yet the parties announce that the construction will commence shortly, and the facility is expected to be ready for cultivation in Q1-2020. In the meantime, Stenocare will continue its already initiated initial cultivation in order to secure the ability to produce with consistency. Cultivation is developed in close cooperation with and based upon intense tech-/knowledge transfer from our partner and shareholder, CannTrust in order to set new standards for best-of-breed cultivation.
The decision to establish premium manufacturing at scale is a natural consequence of Stenocare’s recent announcement that it has commenced its cultivation on Danish grounds and marks the next step towards establishing Stenocare as a frontrunner and global premium brand.
Thomas Schnegelsberg, CEO of Stenocare, comments: “Our Production Director, Søren Kjær, has been working intensively with the specialists at our partner, Havecon Horticultural Projects to arrive at today’s important announcement that we will establish a highly innovative and industry leading cultivation facility. This will play an important role in establishing STENOCARE as a leader in premium medical cannabis”.
Henk Verbakel, CEO of Havecon, comments: “We were impressed and excited from our first contact with Stenocare. We have established over 10 projects for such cultivation worldwide but have never before seen such ambition to create a hybrid that lives up to the benefits of scale from traditional greenhouses while maintaining the benefits of quality from cleanroom type manufacturing. Together with Stenocare, we have developed just that. I am very proud of our cooperation and the team”.